RMS Pty Revenue and Competitors

AU

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • RMS Pty's estimated annual revenue is currently $2.9M per year.(i)
  • RMS Pty's estimated revenue per employee is $101,500

Employee Data

  • RMS Pty has 29 Employees.(i)

RMS Pty's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.6M877%N/AN/A
#2
$8M61N/AN/AN/A
#3
$4.4M38N/AN/AN/A
#4
$2.8M29N/AN/AN/A
#5
$3.9M34N/AN/AN/A
#6
$2.9M29N/AN/AN/A
#7
$0.8M6N/AN/AN/A
#8
$4.2M36N/AN/AN/A
#9
$3.6M31N/AN/AN/A
#10
$7.2M55-8%N/AN/A
#11
$1M12N/AN/AN/A
#12
$182.2M574N/AN/AN/A
#13
$105.1M331N/AN/AN/A
#14
$2.1M21N/AN/AN/A
#15
$96.2M303N/AN/AN/A
#16
$7.5M37N/AN/AN/A
#17
$2.3M15N/AN/AN/A
#18
$5.3M46N/AN/AN/A
#19
$0.6M8N/AN/AN/A
#20
$1.4M16N/AN/AN/A
Add Company

What Is RMS Pty?

keywords:N/A

N/A

Total Funding

29

Number of Employees

$2.9M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

RMS Pty News

2022-04-17 - ABBV SHAREHOLDER ALERT: Jakubowitz Law Reminds AbbVie Shareholders of a Lead Plaintiff Deadline of June 6, 2022

sclerosis (RMS), Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced today. ZINBRYTA is a once-monthly, self-administered,

2022-04-17 - GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ABBV

sclerosis (RMS), Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced today. ZINBRYTA is a once-monthly, self-administered,

2022-04-17 - The Gross Law Firm Announces Class Actions on Behalf of Shareholders of CELH, VLTA and ABBV

sclerosis (RMS), Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced today. ZINBRYTA is a once-monthly, self-administered,

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2M2932%$7M
#2
$7.5M290%N/A
#3
$5M297%N/A
#4
$2.9M29N/AN/A
#5
$1.7M29N/AN/A